Omalizumab for urticaria treatment in clinical practice: a case series

INTRODUCTION: Omalizumab (Xolair) originally intended to reduce symptoms of moderate to severe asthma uncontrollable with steroids is the first monoclonal antibody approved for treatment of chronic spontaneous urticaria in 2014. AIM: To evaluate response and potential side effects to omalizumab trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Lesiak, Aleksandra, Bednarski, Igor A., Maćkowska, Anna, Łukasik, Zuzanna, Woźniacka, Anna, Olejniczak-Staruch, Irmina, Narbutt, Joanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Termedia Publishing House 2018
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130138/
https://www.ncbi.nlm.nih.gov/pubmed/30206449
http://dx.doi.org/10.5114/ada.2018.77666

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6130138/
https://www.ncbi.nlm.nih.gov/pubmed/30206449
http://dx.doi.org/10.5114/ada.2018.77666

Ejemplares similares